Novadaq Technologies Inc.
TSX : NDQ

Novadaq Technologies Inc.

July 16, 2008 09:00 ET

Novadaq to Release Q2-08 Financial Results on July 30-Conference Call to Follow

TORONTO, ONTARIO--(Marketwire - July 16, 2008) - Novadaq® Technologies Inc. (TSX:NDQ), a developer of real-time medical imaging and image guidance systems for the operating room, will announce its second quarter 2008 financial results prior to the market opening on Wednesday, July 30, 2008.

Novadaq is pleased to invite all interested parties to participate in a conference call on July 30 at 10:00 a.m. Eastern Time during which the results will be discussed.

Those wishing to access the live conference call by telephone should dial 1-866-223-7781 (within Canada and the United States) or 416-641-6119 (international callers) several minutes prior to the beginning of the call. A telephonic replay of the conference call will be made available until August 13, 2008 at midnight and can be accessed by dialing 416-695-5800 and entering the pass code 3266650 followed by the number sign when prompted.

The call will also be webcast live and archived for 365 days on the company's website at www.novadaq.com under the "Events" tab in the Investors section. In addition, a replay of the call will be available for download to a portable audio player or computer as an MP3, or podcast, file at the same location on Novadaq's website.

About Novadaq Technologies

Novadaq Technologies Inc. commercializes real-time imaging and image guidance systems for use in the operating room. With one set of proprietary core technologies, Novadaq's products have multiple applications. Novadaq's SPY® System enables cardiac surgeons to diagnose intra-operatively by visually assessing coronary vasculature and bypass graft functionality during the course of heart bypass surgery. The SPY System is also indicated for use during other surgeries, such as cardiovascular, plastic, reconstructive, organ transplant and urological procedures. SPY can be used to visualize blood vessels, tumors, tumor margins and the lymphatic system. Novadaq introduced PINPOINT™, its first minimally invasive imaging system for autofluorescence, in October 2007. PINPOINT allows surgeons to differentiate between healthy and cancerous tissue in the lung and other hollow organs. Further expanding its portfolio of minimally invasive products, Novadaq is developing SPYscope which combines the typical features of a standard endoscope with the additional capabilities of SPY imaging. Novadaq is the exclusive United States distributor of PLC Medical's CO2 HEART LASER System, used in the same cardiac procedures as the SPY System. Novadaq also offers the OPTTX® System, which leverages the company's core imaging technology and is designed for the diagnosis, evaluation and treatment of wet Age-related Macular Degeneration (AMD). For more information, please visit the company's website at www.novadaq.com.

Forward-Looking Statements

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Novadaq's current beliefs as well as assumptions made by and information currently available to Novadaq and relate to, among other things, results of future clinical tests of PINPOINT and the SPY System, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information